Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
A. Gasmi, Guilhem Roubaud, Charles Dariane, Éric Barret, Jean‐Baptiste Beauval, L. Brureau, G. Créhange, G. Fiard, Gaëlle Fromont, Mathieu Gauthé, A. Ruffion, Raphaële Renard‐Penna, Paul Sargos, Morgan Rouprêt, Guillaume Ploussard, Romain Mathiéu
Abstract
Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.